News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galapagos NV (GLPG.BR) Awarded Grant To Accelerate Drug Discovery


2/11/2009 12:00:48 PM

MECHELEN, BELGIUM--(Marketwire - February 11, 2009) - Galapagos NV (Euronext: GLPG) announces today that it has been awarded a EUR 837,000 grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). Galapagos will elucidate the structure of novel drug targets and related small molecules in its bone & joint disease portfolio.

The two-year project "Drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors" focuses on Galapagos' novel drug targets and the candidate drugs that bind to these targets. This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the renowned Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).

"This grant gives us an opportunity to collaborate with the VIB's top structural biology group, thereby adding to our drug discovery capabilities," said Graham Dixon, SVP Drug Discovery for Galapagos. "Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone & joint diseases."

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. It has established risk sharing alliances with GSK, Janssen Pharmaceutica, Eli Lilly and Merck. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. Galapagos currently employs 470 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com.

About the Structural Biology Brussels Lab

The Structural Biology Brussels Lab, headed by Jan Steyaert was founded by Lode Wyns in the seventies at the Vrije Universiteit Brussel and is one of the Flanders Institute for Biotechnology departments. The understanding of the function of a protein, from its structure to its dynamics, remains the central theme of the lab. The multidisciplinary team of about 40 researchers is housed in new laboratory facilities and combines extensive expertise in biophysics and molecular biology. More information at: www.structuralbiology.be.

CONTACT
Galapagos NV
Graham Dixon, SVP Drug Discovery
Tel: +32 473 86 87 51
ir@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.


Copyright © Hugin AS 2009. All rights reserved.




Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES